BACKGROUND: YKL-40 is a chitinase-like protein that, in cross-sectional clinical studies, has been associated with severe asthma and COPD in smokers. AIM: To determine the longitudinal relation of circulating YKL-40 to levels and decline of lung function in the general population. METHODS: We used longitudinal data from up to 13 surveys from the population-based TESAOD study which was conducted in Tucson, Arizona between 1972 and 1996. In cross-sectional analyses, we also used data from 3 Spanish centers of the multicenter ECRHS study (ECRHS-Sp). Serum YKL-40 was measured at baseline in TESAOD and in survey 2 in ECRHS-Sp using ELISAs. Multivariate linear regression was used to test associations of serum YKL-40 to concomitant lung function. In TESAOD, random coefficients models were used to test associations of serum YKL-40 to subsequent decline of lung function. RESULTS: Data on YKL-40 and lung function were available from 1088 TESAOD and 854 ECRHS-Sp adult participants (59% and 51% females; respectively). In adjusted multivariate meta-analyses, being in the highest YKL-40 quartile was associated cross-sectionally with significant deficits in FEV1 and FVC %predicted. In adjusted longitudinal analyses, TESAOD participants in the top YKL-40 quartile had an FEV1 decline that was 5 ml/yr (p = 0.05) faster than subjects in the third quartile, 5 ml/yr (p = 0.02) faster than subjects in the second quartile, and 10 ml/yr (p < 0.001) faster than subjects in the lowest YKL-40 quartile. These longitudinal effects were particularly strong in smokers and absent in never smokers. After adjusting for covariates, as compared with the other three quartiles combined, the top YKL-40 quartile was associated with a 9 ml/yr (p = 0.001) faster FEV1 decline among smokers, while no significant effects were found among never smokers (2 ml/yr, p = 0.35). CONCLUSIONS: Circulating YKL-40 is associated with levels and decline of lung function in the general population and may be a biomarker of susceptibility to the long-term effects of cigarette smoking.
BACKGROUND:YKL-40 is a chitinase-like protein that, in cross-sectional clinical studies, has been associated with severe asthma and COPD in smokers. AIM: To determine the longitudinal relation of circulating YKL-40 to levels and decline of lung function in the general population. METHODS: We used longitudinal data from up to 13 surveys from the population-based TESAOD study which was conducted in Tucson, Arizona between 1972 and 1996. In cross-sectional analyses, we also used data from 3 Spanish centers of the multicenter ECRHS study (ECRHS-Sp). Serum YKL-40 was measured at baseline in TESAOD and in survey 2 in ECRHS-Sp using ELISAs. Multivariate linear regression was used to test associations of serum YKL-40 to concomitant lung function. In TESAOD, random coefficients models were used to test associations of serum YKL-40 to subsequent decline of lung function. RESULTS: Data on YKL-40 and lung function were available from 1088 TESAOD and 854 ECRHS-Sp adult participants (59% and 51% females; respectively). In adjusted multivariate meta-analyses, being in the highest YKL-40 quartile was associated cross-sectionally with significant deficits in FEV1 and FVC %predicted. In adjusted longitudinal analyses, TESAOD participants in the top YKL-40 quartile had an FEV1 decline that was 5 ml/yr (p = 0.05) faster than subjects in the third quartile, 5 ml/yr (p = 0.02) faster than subjects in the second quartile, and 10 ml/yr (p < 0.001) faster than subjects in the lowest YKL-40 quartile. These longitudinal effects were particularly strong in smokers and absent in never smokers. After adjusting for covariates, as compared with the other three quartiles combined, the top YKL-40 quartile was associated with a 9 ml/yr (p = 0.001) faster FEV1 decline among smokers, while no significant effects were found among never smokers (2 ml/yr, p = 0.35). CONCLUSIONS: Circulating YKL-40 is associated with levels and decline of lung function in the general population and may be a biomarker of susceptibility to the long-term effects of cigarette smoking.
Authors: Julia S Johansen; Tine Lottenburger; Hans Jørgen Nielsen; Jens Erik B Jensen; Mads N Svendsen; Gine Kollerup; Ib J Christensen Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-10 Impact factor: 4.254
Authors: J M Antó; J Sunyer; X Basagaña; R Garcia-Esteban; I Cerveri; R de Marco; J Heinrich; C Janson; D Jarvis; M Kogevinas; N Kuenzli; B Leynaert; C Svanes; M Wjst; T Gislason; P Burney Journal: Allergy Date: 2010-02-04 Impact factor: 13.146
Authors: Geoffrey L Chupp; Chun Geun Lee; Nizar Jarjour; Yun Michael Shim; Carole T Holm; Susan He; James D Dziura; Jennifer Reed; Anthony J Coyle; Peter Kiener; Mark Cullen; Martine Grandsaigne; Marie-Christine Dombret; Michel Aubier; Marina Pretolani; Jack A Elias Journal: N Engl J Med Date: 2007-11-15 Impact factor: 91.245
Authors: Carole Ober; Zheng Tan; Ying Sun; Jennifer D Possick; Lin Pan; Raluca Nicolae; Sadie Radford; Rodney R Parry; Andrea Heinzmann; Klaus A Deichmann; Lucille A Lester; James E Gern; Robert F Lemanske; Dan L Nicolae; Jack A Elias; Geoffrey L Chupp Journal: N Engl J Med Date: 2008-04-09 Impact factor: 91.245
Authors: Chun Geun Lee; Dominik Hartl; Gap Ryol Lee; Barbara Koller; Hiroshi Matsuura; Carla A Da Silva; Myung Hyun Sohn; Lauren Cohn; Robert J Homer; Alexander A Kozhich; Alison Humbles; Jennifer Kearley; Anthony Coyle; Geoffrey Chupp; Jennifer Reed; Richard A Flavell; Jack A Elias Journal: J Exp Med Date: 2009-05-04 Impact factor: 14.307
Authors: Louise V Wain; Ian Sayers; María Soler Artigas; Michael A Portelli; Eleftheria Zeggini; Ma'en Obeidat; Don D Sin; Yohan Bossé; David Nickle; Corry-Anke Brandsma; Anders Malarstig; Ciara Vangjeli; Scott A Jelinsky; Sally John; Iain Kilty; Tricia McKeever; Nick R G Shrine; James P Cook; Shrina Patel; Tim D Spector; Edward J Hollox; Ian P Hall; Martin D Tobin Journal: PLoS Genet Date: 2014-05-01 Impact factor: 5.917
Authors: Sebastian Majewski; Karolina Szewczyk; Hanna Jerczyńska; Joanna Miłkowska-Dymanowska; Adam J Białas; Łukasz Gwadera; Wojciech J Piotrowski Journal: Front Immunol Date: 2022-02-10 Impact factor: 7.561
Authors: Ines Mack; Andreas Hector; Marlene Ballbach; Julius Kohlhäufl; Katharina J Fuchs; Alexander Weber; Marcus A Mall; Dominik Hartl Journal: Mol Cell Pediatr Date: 2015-02-27